



# STARS

STRENGTHENING  
REGULATORY  
SCIENCE

## Why the CSA STARS and the Common Strategy is needed

**Wolfgang Ballensiefen (DLR)**  
**STARS partner**

**Second European Stakeholder Workshop**  
November 17<sup>th</sup>/18<sup>th</sup>, 2021




This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825881

Classified as internal/staff & contractors by the European Medicines Agency

## Why the CSA STARS and its Common Strategy is needed?

- To accelerate the **successful** and **timely implementation** of academic research for the benefit of the **patients**?
- To communicated the **need** and **benefit** of regulatory processes and frameworks.
- To support the fruitful and fair cooperation between **academia** and **industry** and ensure suitable and reproducible research results and innovations.
- To improve the **impact** of academic biomedical research for the health systems.
- To optimised the use of **public research funding** by increasing the number of **new drugs** and **therapies** parallel to the knowledge gain and related publications.

## STARS Activities which support the development of the “Common Strategy”



## The STARS Common Strategy

### What is the Common Strategy?

A **strategic** document, incl. **recommendations** to improve the regulatory awareness, knowledge and skills of academia as well as regulators.


### What does it include?

- A description of the **European status** and the **achievements** of the STARS consortium.
- **Recommendations** based on survey data, evaluation of the pilots, input from stakeholders and experts also via the 1<sup>st</sup> and this 2<sup>nd</sup> STARS workshop.

### To whom is it addressed?

- **European Commission**, stakeholder across Europe and the member states & regions (e.g. academia, NCAs, ministries, policy, funders, industry, provider, payer and the public).
- **9 European Partnerships** in the cluster health: Innovative Health Initiative, Personalised Medicine, Rare diseases, Pandemic Preparedness, ERA4Health, Transforming of Health Systems, Global Health, OneHealth/AMR & Chemicals Risk Assessment

## The STARS Common Strategy - Chapters



## The STARS Common Strategy - A

21 recommendations in six target groups & strategic areas

**(1) Regulatory  
Authorities in Europe**

**(2) Academic  
Researcher and  
Institutions**

**(3) European  
Commission,  
Ministries and  
Funders**

**(4) Industry**

**(5) Education**

**(6) Cross-cutting  
recommendations**

## STARS Common Strategy

### “Status, Challenges and Opportunities for Regulatory Advice for Academia”

- The “Common Strategy” is *work in progress* and will be further developed, also by the valuable contributions of this workshop.
- Thus the presentations and discussion from the panel and the break-out sessions will be considered for this further development.
- This document should not only be developed by and for the regulatory community! Thus, **you have been and will be a crucial part of this process!**
- Therefore, you have now another opportunity to give your view and input!
- You can also send your ideas and feedback after the event, but latest until **mid-December 2021** to STARS via mail.
- The launch and presentation of the STARS “Common Strategy” will be in **May 2022** at a final conference.